Cerus (NASDAQ:CERS) Reaches New 12-Month High After Better-Than-Expected Earnings

Cerus Corporation (NASDAQ:CERS) shares hit a new 52-week high during trading on Friday following a better than expected earnings announcement. The stock traded as high as $3.15 and last traded at $2.86, with a volume of 7017316 shares trading hands. The stock had previously closed at $2.03.

The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. The business had revenue of $59.89 million during the quarter, compared to the consensus estimate of $55.68 million.

Trending Headlines about Cerus

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Q1 results beat expectations — Cerus reported revenue of ~$59.9M (up ~22.6% YoY) and EPS of -$0.01, topping estimates and showing a sharply reduced net loss; operating cash flow was positive (~$6.2M) and cash on hand ~$27.9M. Those fundamentals are the primary reason the stock is trading higher. Quiver Quantitative: CERS Stock Rises on Q1 2026 Earnings
• Positive Sentiment: Analyst upgrade: BTIG Research moved CERS from “neutral” to “buy” with a $4.00 price target (roughly double current levels), which supports upside sentiment and may attract momentum buyers. Benzinga: BTIG Upgrade
• Neutral Sentiment: Earnings call / disclosure: Full Q1 earnings call transcript and press materials were released for investors to parse product, margin and commercial commentary — useful for sizing ongoing growth drivers but not new price catalysts by themselves. Seeking Alpha: Q1 2026 Earnings Call Transcript
• Negative Sentiment: FY?2026 revenue guidance was updated to $227.0M–$231.0M, below the consensus (~$233.9M). That guidance shortfall is a headwind and likely the main reason some investors are taking profits or re?rating estimates. MarketBeat: FY2026 Guidance
• Negative Sentiment: Insider selling: multiple executives have sold shares in the past six months (no recent purchases reported), which can raise governance or conviction questions for some investors. Quiver Quantitative: Insider Activity

Analysts Set New Price Targets

CERS has been the topic of a number of recent analyst reports. BTIG Research upgraded shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Friday. TD Cowen reiterated a “buy” rating on shares of Cerus in a report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cerus in a report on Wednesday, March 25th. Wall Street Zen cut shares of Cerus from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Zacks Research cut shares of Cerus from a “hold” rating to a “strong sell” rating in a report on Thursday, March 12th. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $4.00.

Insider Buying and Selling

In related news, insider Chrystal Jensen sold 30,845 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $2.01, for a total value of $61,998.45. Following the sale, the insider owned 1,059,139 shares in the company, valued at approximately $2,128,869.39. This trade represents a 2.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Dennis Green sold 127,544 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $1.66, for a total transaction of $211,723.04. Following the completion of the sale, the chief financial officer owned 1,040,551 shares in the company, valued at $1,727,314.66. This represents a 10.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,194,282 shares of company stock valued at $2,106,290 in the last ninety days. Corporate insiders own 5.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Cerus by 0.6% in the third quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock worth $17,147,000 after acquiring an additional 62,663 shares during the period. Wasatch Advisors LP raised its position in Cerus by 2.6% in the second quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock worth $12,033,000 after acquiring an additional 213,917 shares during the period. Millennium Management LLC raised its position in Cerus by 17.6% in the third quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock worth $5,517,000 after acquiring an additional 519,301 shares during the period. Ieq Capital LLC raised its position in Cerus by 1.1% in the fourth quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company’s stock worth $4,993,000 after acquiring an additional 25,771 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in Cerus by 5.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,676,279 shares of the biotechnology company’s stock worth $3,453,000 after acquiring an additional 92,577 shares during the period. 78.37% of the stock is currently owned by institutional investors.

Cerus Stock Up 40.1%

The company has a debt-to-equity ratio of 0.62, a current ratio of 1.73 and a quick ratio of 1.17. The firm has a market capitalization of $570.05 million, a P/E ratio of -35.19 and a beta of 1.63. The company’s 50-day simple moving average is $1.97 and its two-hundred day simple moving average is $1.98.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.